
First approved for adults in 2022, the therapy is now cleared for children 12-18 with symptomatic obstructive hypertrophic cardiomyopathy.
Net profits may have fallen but independent pharmacy owners earned, in terms of 2003 dollars, $200,000 compared to $61,000 when the Lilly Digest began tracking the sector in 1932, according to a new study.






